Skip to main content
letter
. 2022 Dec 12;73(1):58–60. doi: 10.1111/pin.13291

Figure 1.

Figure 1

Genetic characterization of in situ follicular neoplasia (ISFN) in a young liver‐transplant patient. (a) Identification of ISFN by BCL2 immunohistochemistry. ISFN lesions indicated by arrows. (b) Targeted sequencing of 191 genes (frequently mutated in follicular lymphoma and diffuse large B‐cell lymphoma) identifies a single mutation, namely TNFRSF14 c.G136T, p.E46*, which predicts a truncated protein product. (c) BCL2‐IGHJ PCR (MBR1) (BIOMED‐2 Reaction A assay) shows a positive product for the inguinal lymph node (LN), but not the axillary LN biopsy (left panel). Clone‐specific PCR demonstrates an expected 89 bp product from the inguinal LN biopsy, but not the axillary LN biopsy (right panel). Nucleotides in red color (bottom panel) are nontemplate random insertions between the BCL2 and IGHJ genes.